Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer.
A chemotherapy-free combination showed promising response rates in previously treated pancreatic cancer with specific genetic mutations.
This phase 2 clinical trial evaluates Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer. The PubMed abstract reports that In the RP2D cohort (n = 37), the confirmed objective response rate was 43;2% (95% confidence interval [CI], 27;1-60;5), disease control rate was 81;1% (95% CI, 64;8-92;0), median duration of response was 6;9 months (95% CI, 4;8-8;6), median progression-free survival was 5;7 months (95% CI, 4;0-7;5), and median overall survival.
What the study was
- Study design
- Phase 2 clinical trial
- Population
- Human participants described in the PubMed abstract
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cancer cell
Why it surfaced
Phase 2 clinical trial with human evidence; scored conservatively from PubMed abstract-level metadata.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.